- Home
- EAD vs VSTM Comparison
EAD vs VSTM Comparison
Compare EAD & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$8.07
Company Overview
Basic Information| Metric | EAD | VSTM |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.0M | 395.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | EAD | VSTM |
|---|---|---|
| Price | $6.41 | $8.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 233.2K | ★ 2.0M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $6.24 | $3.43 |
| 52 Week High | $7.15 | $11.25 |
Technical Indicators
Market Signals| Indicator | EAD | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 72.40 |
| Support Level | $6.37 | $7.59 |
| Resistance Level | $6.45 | $8.88 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 75.00 | 98.78 |
Price Performance
Historical Comparison EAD
VSTM
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. The Fund seeks a high level of current income. Capital appreciation is a secondary objective. The fund has single operating segment.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.